Sweden's Bactiguard Q4 revenue beats estimates

Reuters

02/05

Sweden's Bactiguard Q4 revenue beats estimates

Overview

Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted
Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln
Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln

Outlook

Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026
Company plans to secure additional partnerships and support existing partners in 2026
Bactiguard to enhance operational efficiency to support growth and profitability

Result Drivers

ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business
HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas
CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	SEK 65.60 mln	SEK 51 mln (1 Analyst)
Q4 Adjusted EPS		SEK 0.36
Q4 Net Income		SEK 12.50 mln
Q4 EBITDA		SEK 24.70 mln
Q4 Operating Cash Flow		SEK 11.70 mln
Q4 Operating Profit		SEK 13 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85

Press Release: ID:nWkrbhS21N

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2609771340"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609771340\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609771340?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609771340","market":"nz","top_or_hot":-1,"title":"Sweden's Bactiguard Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Bactiguard Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted</p></li><li><p>Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln</p></li><li><p>Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026</p></li><li><p>Company plans to secure additional partnerships and support existing partners in 2026</p></li><li><p>Bactiguard to enhance operational efficiency to support growth and profitability</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business</p></li><li><p>HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas</p></li><li><p>CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>SEK 65.60 mln</p></td><td><p>SEK 51 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td></td><td><p>SEK 0.36</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>SEK 12.50 mln</p></td><td></td></tr><tr><td><p>Q4 EBITDA</p></td><td></td><td><p>SEK 24.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Cash Flow</p></td><td></td><td><p>SEK 11.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Profit</p></td><td></td><td><p>SEK 13 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85</p></li></ul><p>Press Release: <span>ID:nWkrbhS21N</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's Bactiguard Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's Bactiguard Q4 revenue beats estimates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-05 14:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's Bactiguard Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted</p></li><li><p>Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln</p></li><li><p>Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026</p></li><li><p>Company plans to secure additional partnerships and support existing partners in 2026</p></li><li><p>Bactiguard to enhance operational efficiency to support growth and profitability</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business</p></li><li><p>HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas</p></li><li><p>CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>SEK 65.60 mln</p></td><td><p>SEK 51 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td></td><td><p>SEK 0.36</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>SEK 12.50 mln</p></td><td></td></tr><tr><td><p>Q4 EBITDA</p></td><td></td><td><p>SEK 24.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Cash Flow</p></td><td></td><td><p>SEK 11.70 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Profit</p></td><td></td><td><p>SEK 13 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85</p></li></ul><p>Press Release: <span>ID:nWkrbhS21N</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0310799852.SGD","symbol_name":"FTIF - Templeton Global Equity Income A MDIS SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL1N3Z1083:1","article_id":"2609771340","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609771340","pubTimestamp":1770271983,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's Bactiguard Q4 revenue beats estimatesOverviewSwedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjustedQ4 operating profit improved to SEK 13.0 mln from SEK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4082":"医疗保健设备","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4504":"桥水持仓","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4588":"碎股","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","ZBH":"齐默巴奥米特控股","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4566":"资本集团","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD"},"translate_title":"瑞典Bactiguard第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":0.9},"content_text":"Sweden's Bactiguard Q4 revenue beats estimatesOverviewSwedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjustedQ4 operating profit improved to SEK 13.0 mln from SEK -3.2 mlnCompany's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mlnOutlookBactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026Company plans to secure additional partnerships and support existing partners in 2026Bactiguard to enhance operational efficiency to support growth and profitabilityResult DriversZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license businessHYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areasCURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued productsKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeatSEK 65.60 mlnSEK 51 mln (1 Analyst)Q4 Adjusted EPSSEK 0.36Q4 Net IncomeSEK 12.50 mlnQ4 EBITDASEK 24.70 mlnQ4 Operating Cash FlowSEK 11.70 mlnQ4 Operating ProfitSEK 13 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy.\"Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85Press Release: ID:nWkrbhS21NFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}